TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
NG Daver, A Maiti, TM Kadia, P Vyas, R Majeti, AH Wei… - Cancer discovery, 2022 - AACR
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
Genetics of MDS
S Ogawa - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …
myeloid disorders has been dramatically improved during the past decade, in which …
Molecular international prognostic scoring system for myelodysplastic syndromes
E Bernard, H Tuechler, PL Greenberg… - NEJM …, 2022 - evidence.nejm.org
Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS …
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS …
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
EJ Duncavage, A Bagg, RP Hasserjian… - Blood, The Journal …, 2022 - ashpublications.org
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Abstract Tumor protein p53 (TP53) is the most frequently mutated gene in cancer,. In
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …
Age-related remodelling of oesophageal epithelia by mutated cancer drivers
A Yokoyama, N Kakiuchi, T Yoshizato, Y Nannya… - Nature, 2019 - nature.com
Clonal expansion in aged normal tissues has been implicated in the development of cancer.
However, the chronology and risk dependence of the expansion are poorly understood …
However, the chronology and risk dependence of the expansion are poorly understood …
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs).
Despite an increasing number of publications, many important features of DDX41-mutated …
Despite an increasing number of publications, many important features of DDX41-mutated …
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT
O Penack, C Peczynski, M Mohty… - Blood …, 2020 - ashpublications.org
We performed a study to find out how advances in modern medicine have improved the
mortality risk of allogeneic stem cell transplantation. We analyzed major transplantation …
mortality risk of allogeneic stem cell transplantation. We analyzed major transplantation …
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
DA Sallman, AF McLemore, AL Aldrich… - Blood, The Journal …, 2020 - ashpublications.org
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic
syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations …
syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations …
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS).
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …